(Go: >> BACK << -|- >> HOME <<)
Jump to content

PEAQX

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Meodipt (talk | contribs) at 09:32, 27 July 2008. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

PEAQX
Clinical data
Other namesPEAQX
Identifiers
  • ({[(1S)-1-(4-bromophenyl)ethyl]amino}-(2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl)phosphonic acid
Chemical and physical data
FormulaC17H17BrN3O5P
Molar mass454.211 g/mol g·mol−1
3D model (JSmol)
  • O=c2nc1c(nc2=O)cccc1C(P(O)(O)=O)NC(C)c3ccc(Br)cc3

PEAQX is a competitive antagonist at the NMDA receptor. It is subtype-selective, with a 100x selectivity for NMDA receptors composed of 1A/2A subunits vs the 1A/2B subunit composition. It is also a potent anticonvulsant in animal tests.[1]


References

  1. ^ Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R, Schmutz M. 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorganic and Medicinal Chemistry Letters. 2002 Apr 8;12(7):1099-102. PMID 11909726
Retrieved from "https://en.wikipedia.org/w/index.php?title=PEAQX&oldid=228161996"